To examine whether graft-versus-host-disease (GVHD) is associated with a graft-versus-leukaemia (GVL) effect that also influences the outcome of allogeneic stem cell transplantation (SCT) in childhood acute leukaemia, we evaluated all consecutive (n ¼ 169) children who had undergone SCT for ALL and AML at our centre. Median followup was 7 years. The 5-year probability of chronic GVHD was 34%. Median time to relapse was 24 months in children with chronic GVHD and 6 months in those without. The corresponding 5-year probabilities of relapse were 30 and 45% (P ¼ 0.01). The 5-year probability of survival was 54%. Patients with chronic GVHD had a significantly better survival, 77 vs 51% (P ¼ 0.01). In a Cox regression model, chronic GVHD independently decreased the risk of relapse (RR 0.44) and further predicted an increased chance of relapse-free survival (RR 1.7) and survival (RR 2.6). The impact of chronic GVHD on survival was most apparent in late-stage disease and in ALL. Acute GVHD was not an independent predictor for relapse or death in this study. This study is in support of a GVL effect in childhood leukaemia related to chronic GVHD, reducing the risk of relapse and improving survival.
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The major cause of failure after haematopoietic stem cell transplantation (SCT) in childhood leukaemia is relapse of disease, followed by transplant-related causes such as graftversus-host disease (GVHD), treatment toxicity and infections. 1, 2 The original concept of SCT was to enable complete eradication of malignant cells by a maximum dose of chemoradiotherapy, bypassing the otherwise dose-limiting bone marrow aplasia with a salvaging autologous or allogeneic graft. In addition, now a well-established belief in the immunotherapeuthic potential of the allogeneic graft has evolved, usually described as the graft-versus-leukaemia (GVL) effect. This antileukaemia effect was first postulated in the 1950s by Barnes 3 and later reported in humans by Weiden et al 4 in 1979. Acute and chronic GVHD were presented as favourable in decreasing the risk of relapse.
This was later confirmed in an IBMTR study in 1990, 5 which further supported the existence of a GVL effect by reporting a higher probability of relapse in patients receiving T-cell-depleted (TCD) or syngeneic grafts. Several recent studies, including those on the effect of donor lymphocyte infusions (DLI), have strengthened this concept. [6] [7] [8] [9] However, treatment of relapses post-SCT with DLI has been considerably less successful for acute leukaemias than in CML. 9 In a previous study, comparing the outcomes of MUD and sibling graft recipients, we found a significant difference in occurrence of relapse between children who did or did not develop chronic GVHD. 2 We decided to further investigate this issue in the entire group of children transplanted for acute leukaemias at our centre. The aim of the present study was thus to examine whether a GVL effect also is present in the paediatric setting and to relate it to the occurrence of GVHD.
Patients and methods

Patients
A total of 169 SCTs were performed in children with acute leukaemia at Huddinge University Hospital from July 1980 to December 2000. Out of these children 112 had ALL and 57 had AML. The median age at time at SCT was 9 years (range 0.5-17 years). One-third of the patients (58/169) had early-stage disease (CR1), while the rest had more advanced disease (XCR 2), including 22 patients who were not free of disease at transplantation (Table 1 ). In the AML group, 56% of the patients were in CR1 at SCT, while 23% were in CR1 in the larger ALL group (Po0.001). The use of unrelated donors has increased over time and involves all diagnostic groups.
Stem cell source and donor histocompatibility
In all, 139 children were transplanted with HLA-A, -B and DRB1 compatible grafts, donated by 104 siblings, and there were one twin, four other relatives and 32 unrelated donors. Of the patients, 15 received a major HLA-antigenmismatched (MM) graft from a relative. Six patients received a major, and nine patients a minor HLAmismatched graft from an unrelated donor. For HLA class I antigens, HLA-A and -B, typing was performed serologically while class II antigens were determined using genomic methods. Initially, RFLP was used with the help of cDNA probes to determine the DRB, DQA and DQB alleles. Since July 1992 PCR, utilising sequence-specific primer pairs, has been used to define the DRB1-5, DQA1, DQB, DPB1 and more recently the DPA1 alleles. 10 The majority of children received bone marrow grafts while 14 patients received PBSCs.
Conditioning
Patients were prepared with cyclophosphamide (CY) 60 mg/kg/day for 2 days (total dose 120 mg/kg) given in combination with busulphan (BU) 1 mg/kg Â 4/day for 4 days (total dose 16 mg/kg) in 19 patients or in combination with TBI for the remaining 150 patients. A measure of 10 Gy of single fraction TBI was given to 122 patients, two patients receiving a TCD graft received 7.5 Gy and the remaining 26 patients received 12-14.4 Gy of fractionated TBI. 11 Antithymocyte globuline (ATG) or Orthoclone OKT-3 (Jansen-Cilag AB, Sweden) was given for 5 days before BMT to 49 patients receiving unrelated or mismatched grafts. 12 Of all, 10 MM donor grafts were T-cell depleted in vitro using monoclonal antibodies and immunomagnetic beads. In patients with leukaemia in incomplete remission or Ph+ALL, etoposide (900 mg/m 2 ) was added.
Post-BMT immunosuppression and supportive care
A total of 60 patients received monotheraphy with MTX according to the Seattle protocol, or CsA 13 as GVHD prophylaxis. Since August 1985, CsA has been given in combination with a short course of i.v. MTX.
14 After 3-6 months the CsA dose was tapered and withdrawn after 9-12 months in most cases. Prolonged treatment was given to patients with chronic GVHD.
Intrathecal prophylaxis with MTX or cytarabine was given to all patients with leukaemia until November 1988, after which it was only administered to patients with ALL, AML M4 or M5 or with a history of CNS disease.
Antimicrobial prophylaxis included trimetoprim-sulphamethoxazole, various antifungal drugs as well as acyclovir to HSV seropositive patients. Since 1992, pre-emptive antiviral treatment was given in CMV-PCR positive cases.
2,15
Diagnosis and treatment of GVHD Both acute and chronic GVHD were diagnosed on the basis of clinical symptoms. Biopsies were not routinely performed to confirm anything other than gastrointestinal GVHD. Acute GVHD was graded on a scale from 0 (absent) to IV (severe) according to published clinical criteria. 16, 17 Chronic GVHD was classified as mild, moderate or severe (I-III) according to the judgement of the treating physician. 18, 19 In this study, however, only the presence or absence of chronic GVHD was taken into account. GVHD grading over the years was performed and verified according to the protocol by the same team of three senior clinicians.
Acute GVHD was treated with prednisolone 2 mg/kg/ day. If possible, the dose was gradually tapered after 1 Years follow-up, median 7.0 year (1-248 months)
ALL -acute lymphoblastic leukaemia; AML -acute myelogenous leukaemia; ATG -antithymocyte globulin; BM -bone marrow; BUbusulphan; CML -chronic myelocytic leukaemia, CR -complete remission; CSA -cyclosporine A; Cy -cyclophosphamide; FTBIfractionated TBI; GVHD -graft-versus-host disease; HLA -human leukocyte antigen; MTX -methotrexate; NC -nucleated cells Â 10 8 /kg; PBSC -peripheral blood stem cells; TBI -total body irradiation; TLItotal lymphnode irradiation; TCD-T-cell depleted.
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The end point 'leukaemia relapse' was defined as either bone marrow relapse, that is, 425% leukaemic blasts, as defined by FACS and morphology, or as a localized extramedullary relapse. The Cox proportional-hazards regression model was used for uni-and multivariable analysis of risk factors for relapse, RFS (ie death and relapse) and death. Factors with a P-value of 0.1 or less on univariate analysis were assessed for the following multivariable analysis, which was performed in a backward stepwise manner at a significant level of 0.05.
Statistical analysis
The following potential prognostic variables were included in the univariate analysis:
Status of disease at transplantation (CR1 vs XCR 2), type of donor (related vs unrelated graft), HLAhistocompatibility (HLA-6-loci match vs all major and subtype mismatches), diagnosis; AML vs all other diagnoses, ALL vs all other diagnoses, recipient age (p8 years vs 48 years), recipient age, year of transplantation (1980-1991 vs 1992-2000) , year of transplantation, recipient sex (female recipient vs male recipient), donor age, donor sex, female donor to male recipient vs all others, immunised donor (immunised female donor to male recipient vs all others, ABO-compatibility (ABO match vs ABO mismatch), graft cell dose (p vs 4 the median of 3 Â 10 8 nucleated cells/kg), type of graft (bone marrow vs PBSC), pretransplant donor herpes virus serology for CMV, HSV, VZV, EBV (positive for 0-2 viruses vs positive for 3-4 viruses), pretransplant recipient herpes virus serology (0-2 viruses vs 3-4 viruses), CMV status (negative CMV serology both in donor and recipient vs all others), acute GVHD (acute GVHD grade 0-I vs II-IV), acute GVHD (0 vs grade I-IV) chronic GVHD (no/yes), GVHD prophylaxis (monotherapy vs combination therapy or TCD, (see Table 1 ), type of conditioning (TBI vs BU), conditioning with T-cell antibody (ATG or OKT 3 vs all others).
As long as chronic GVHD remained in the multivariable analysis only patients with chronic GVHD or those surviving at least 90 days post-BMT were included.
The study was approved by the human research ethics committee at Huddinge University Hospital, Karolinska Institutet.
Results
General findings and outcome
Of the 169 patients, 166 (98%) were engrafted. The median time to engraftment (ANC40.5 Â 10 9 /l) was 15 (9-43) days. Seven patients rejected their grafts or had graft failure. The early transplant-related mortality (TRM) at 100 days, which assesses the impact of complications such as incomplete engraftment, GVHD, toxicity and infections was 9%, while the 5-year probability of TRM was 18%. At the end of follow-up, median ¼ 7 years post-SCT, 92 patients (54%) were alive, 45 (27%) had died owing to recurrence of leukaemia while 32 (19%) had died of other causes such as infection, respiratory insufficiency or haemorrhage. In 10 cases, acute GVHD grade III-IV contributed to death.
Acute and chronic GVHD
The incidence of acute GVHD grade I was 52% (n ¼ 88), grade II 14% (n ¼ 22), grade III 5% (n ¼ 8) and grade IV 2% (n ¼ 3), while it was absent in 27% (n ¼ 46) patients. The probability of acute GVHD grade II-IV was 20%.
The 5-year probability of chronic GVHD was 34%. Median time to occurrence of chronic GVHD was 181 days (range 87-1848). The cumulative incidence was lower in children with a related than with an unrelated donor (28 vs 52%, P ¼ 0.06). The difference in probability of chronic GVHD was even more pronounced in recipients of HLAmatched sibling grafts; compared to MUD grafts, 24 and 60%, respectively (Po0.01).
Relapse
The 5-year probability of relapse was 41%. It was not significantly different in children with ALL (44%) and AML (37%). The median time to relapse was 7.3 months (range 1.0-98.4). Of the 56 relapses, 38 occurred within the first year post-SCT.
Chronic GVHD decreased the probability of relapse. Children with chronic GVHD had a probability of relapse of 30% compared to 45% in patients without chronic GVHD (P ¼ 0.01) and their median time to relapse was 24 months, while it was 6 months in patients without chronic GVHD.
The effect of chronic GVHD on time to relapse and on probability of relapse for the ALL and AML patients is illustrated in Figure 1 . In children with ALL, the probability of relapse is reduced from 53 to 30% in the presence of a history of chronic GVHD. The same trend was seen in the AML patients.
The 5-year probability of relapse was markedly higher (55%) in patients in XCR 2 without chronic GVHD, while in patients with either chronic GVHD or in CR1 it varied within 25-35% (P ¼ 0.01) (Figure 2 ).
Survival
The 5-year probability of survival was 54% while the relapse-free survival (RFS) was 49%. The probability of survival 10 years after SCT was 48%. The probabilites of survival between ALL and AML patients or between recipients of related or unrelated grafts were not significantly different (55 vs 51%, P ¼ 0.8). Patients with early disease (CR1) and late disease (XCR 2) had a 10-year probability of survival of 72 and 41%, respectively (Po0.001).
Patients with chronic GVHD had a significantly better survival than those without chronic GVHD (P ¼ 0.01). For patients without GVHD the curve levels off at 50% 5-year post-SCT. While the probability of survival at 5 years was 77% for children with chronic GVHD this curve does not reach its plateau at a 58% level until 10-years post-SCT. Chronic GVHD had a favourable effect on survival both in AML and more significantly in ALL (Po0.01) (Figure 3 ). The 5-year probability of survival for the AML patients was 79 and 61%, respectively, with and without chronic GVHD.
The impact of chronic GVHD on survival was greater in patients with late-stage disease (XCR 2) (P ¼ 0.02) than in patients with early stage disease CR1 where the difference in survival in patients with or without GVHD was not statistically significant (P ¼ 0.3).
Multivariable analysis: correlation between GVHD and relapse and survival
Potential risk factors for the end points death, relapse and 'death or relapse', selected in univariate analysis, were brought into a Cox regression model. In addition to the status of disease (XCR 2), absence of chronic GVHD was the other independent predictor of relapse (Table 2) . Acute GVHD, however, tested as occurring or not, or as grade 0-I vs II-IV, was not identified as a risk factor for relapse in univariate analysis or when introduced into the multivariate analysis. Absence of chronic GVHD remained an independent predictor of the end points death and 'death or relapse' (Table 2 ). Other independent predictors of death were status of disease (XCR 2), HLA mismatch and a positive donor serology for 3-4 viruses.
A repeated multivariable analysis, limited to the 112 patients with ALL, still identified chronic GVHD as an independent predictor of a better outcome by decreasing the risk of relapse (Po0.05) and increasing the chance of survival (P ¼ 0.01) as compared to patients without chronic GVHD. This is also evident in Figure 3 .
Multivariable analysis corrected for transplant year (before and after January 1992) was performed separately for all end points, without loss of significance for any of the predictors identified. Figure 3 Probability of survival after SCT related to the occurrenc of chronic GVHD in children with ALL. The 5-year probability of survival for ALL patients with chronic GVHD was 76% vs 45% without chronic GVHD, P ¼ 0.009.
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Discussion
The aim of the present study was to examine whether a GVL effect is present in a paediatric setting and to relate it to the occurrence of GVHD. A randomised trial in children, CCG-2891, 6 confirmed earlier 21, 22 reports of allogeneic SCT as advantageous compared to chemotherapy or autologous BMT, supporting the idea of a GVL effect in childhood leukaemia.
The association between GVHD and improved leukaemia-free survival (LFS) has previously been described, 4, 5 but has not specifically been addressed in a paediatric cohort. Neither did those studies [4] [5] [6] 21 include recipients of unrelated grafts.
In this study, chronic GVHD, but not acute GVHD, was independently associated with a lower risk of relapse. Moreover, chronic GVHD was an independent determinant for improved survival. These observations thus support the assumption of a GVL effect in children.
In contrast to the finding in this paediatric population, some previous studies, mainly in adults, have shown a favourable effect of acute GVHD grade II-IV on relapse 4, 5, 23 and on overall DFS. 24, 25 Since the TRM is higher in patients with acute GVHD, especially in grade III or IV acute GVHD, this might in part counteract a potential GVL effect.
The discrepancy in positive impact on outcome between acute and chronic GVHD is evident in this paediatric population, which unlike most adult populations reported is restricted to acute leukaemias and characterised by a low incidence of acute GVHD grade II-IV. This trend is still in line with the previous studies by Horowitz et al and Ringde´n et al.
5,26
The 5-year probability of chronic GVHD (36%) was within the range seen in previous studies in paediatric SCT including related and unrelated donor grafts, 22, [27] [28] [29] [30] but lower than in comparable adult material. 18, 19, 31 Age has been identified as an important prognostic factor for chronic GVHD. 31, 32 In line with our finding there is much support for a chronic GVHD-related GVL effect, as demonstrated by a decrease in relapse rates, but it has rarely been shown to improve the survival in previous studies. 4, 5, 7 In this study, however, survival rates are also significantly improved.
Possibly, the GVHD-associated GVL effect might be counterbalanced to a lesser extent by chronic GVHDrelated TRM in children than in adults as chronic GVHD is generally milder and easier to control in the paediatric setting. 2, 11, 30, 31, 33, 34 The beneficial effect of chronic GVHD was evident in ALL as well as in AML patients (Figures 1 and 3) . This is an important observation in a perspective, where the role of a GVL effect has been questioned along with the uncertain efficacy of DLI in acute leukaemias, in contrast to the situation in CML. While response rates of 80% have been reported in CML patients, only 10-15% of patients with relapsed ALL and 20-45% of patients with AML responded to DLI. 9 In this paediatric cohort, the impact of chronic GVHD on relapse as well as on survival was most apparent in the ALL patients.
As expected, leukaemic patients with advanced disease (XCR 2) did, over all, worse than patients transplanted in CR1. In line with transplant referral criteria the proportion of patients with more advanced disease, XCR 2 was significantly higher in the ALL group compared to the AML group. It is remarkable, however, that the ALL patients still have a good overall survival and those who had experienced a course of chronic GVHD had an estimated 5-year survival of 76% ( Figure 3 ). Our data thus suggest that patients with more advanced disease (XCR 2) might actually be the ones that benefit the most from a GVL effect, which also has historical support. 4, 7 The impact of chronic GVHD on relapse and survival, in patients with late-stage disease in particular, has not previously been described in childhood leukaemias. Few previous reports are able to convincingly demonstrate an effect on long-term survival.
Children transplanted with an MUD donor had a higher probability for chronic GVHD compared to recipients of a matched sibling donor. This may explain why we and others have recently observed a probability of survival in MUD-grafted children with ALL that is on par with that of sibling donor transplants. 2, 29, 35 The increased risk of opportunistic infections or pulmonary complications secondary to chronic GVHD did cause some late events affecting the slope of the latter part of the survival curve in patients with chronic GVHD. In the entire cohort of patients there were only two relapses occurring later than 4 years post-SCT and one death from a secondary malignancy. To manage the balance between a leukaemia-specific response and unfavourable extensive GVHD poses a difficult challenge.
Although there are sufficient theoretical and animal data to support a link between GVHD and a GVL effect, there are also clinical and experimental observations of a GVL effect without clinically manifest GVHD activity. 5, 36, 37 A more restricted GVL mechanism could be triggered by specific target antigens on haematopoietic-or leukaemic cells. 38, 39 We have earlier observed that time to relapse is longer in patients receiving an MUD graft compared to those receiving a sibling graft. 2 The long median follow up after SCT in this study revealed an impact on the dynamics of the relapse and survival curves clearly suggestive of a GVHD-associated GVL effect. As the life tables illustrate, there is a 'window of opportunity' after SCT for early detection of residual disease and immunotherapeutic interventions. 38, 39 In conclusion, this study supports an allogeneic GVHDassociated GVL effect in acute childhood leukaemias. Chronic GVHD markedly reduced the risk of relapse, and also had a positive impact on long-term survival, particularly in patients with ALL and in those with more advanced disease.
